https://drugnews.com.tw/articles/2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3-en.html Drugnews｜藥時事 en 2026-10-01T00:00:00.000Z Adding an ADC to Lung Cancer Immunotherapy: More Tumor Responses, but Why Did Phase 3 Fall Short? https://drugnews.com.tw/articles/2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3.html Drugnews｜藥時事 zh-tw 2026-10-01T00:00:00.000Z 肺癌免疫治療再加ADC：腫瘤更常縮小，為何三期仍未過關？ https://drugnews.com.tw/articles/2026-09-30-novo-kallyope-non-incretin-obesity-programs-en.html Drugnews｜藥時事 en 2026-09-30T00:00:00.000Z Novo Nordisk Already Has Weight-Loss Injections. Why Pursue Another Path? https://drugnews.com.tw/articles/2026-09-30-novo-kallyope-non-incretin-obesity-programs.html Drugnews｜藥時事 zh-tw 2026-09-30T00:00:00.000Z 已有瘦瘦針，諾和諾德為何還要布局另一條減重路？